[{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"74305bac-f746-463f-9609-3bbe7cdbf8c8","acronym":"P30CA014089","url":"https://clinicaltrials.gov/study/NCT03049618","created_at":"2021-01-18T15:01:05.004Z","updated_at":"2025-02-25T16:36:52.177Z","phase":"Phase 2","brief_title":"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","source_id_and_acronym":"NCT03049618 - P30CA014089","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRAF • ALK • ROS1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-02-06"},{"id":"2544edc3-fab3-481b-a255-f6f7a7b4ecc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04486781","created_at":"2021-01-18T21:32:20.054Z","updated_at":"2024-07-02T16:35:06.419Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT04486781","lead_sponsor":"Vasgene Therapeutics, Inc","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • sEphB4-HSA"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/14/2020","start_date":" 08/14/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-02"},{"id":"25671921-cedc-4c83-9415-f58675a747fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03993106","created_at":"2021-01-29T07:19:27.297Z","updated_at":"2024-07-02T16:35:06.312Z","phase":"Phase 2","brief_title":"A Study of sEphB4-HSA in Kaposi Sarcoma","source_id_and_acronym":"NCT03993106","lead_sponsor":"Vasgene Therapeutics, Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sEphB4-HSA"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-02"},{"id":"1cb3a87f-6700-43c5-97eb-2ad01d3c6932","acronym":"","url":"https://clinicaltrials.gov/study/NCT02799485","created_at":"2021-01-18T13:44:04.096Z","updated_at":"2024-07-02T16:35:44.581Z","phase":"Phase 2","brief_title":"sEphB4-HSA in Treating Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT02799485","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" EPHB4","pipe":"","alterations":" ","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sEphB4-HSA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-06-27"},{"id":"d6bf4390-80d2-48a6-a20b-b3b33e8ad438","acronym":"","url":"https://clinicaltrials.gov/study/NCT00522145","created_at":"2021-01-18T01:53:09.959Z","updated_at":"2024-07-02T16:36:10.496Z","phase":"Phase 2","brief_title":"Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","source_id_and_acronym":"NCT00522145","lead_sponsor":"Kadmon Corporation, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • tesevatinib (KD019)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/01/2007","start_date":" 05/01/2007","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2022-05-13"},{"id":"aa2c301e-78e0-4981-a17e-6a53b1eb1bc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02616393","created_at":"2021-01-18T12:42:35.477Z","updated_at":"2024-07-02T16:36:15.309Z","phase":"Phase 2","brief_title":"Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases","source_id_and_acronym":"NCT02616393","lead_sponsor":"Kadmon Corporation, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tesevatinib (KD019)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/03/2018","primary_completion_date":" 04/03/2018","study_txt":" Completion: 04/03/2018","study_completion_date":" 04/03/2018","last_update_posted":"2022-03-16"}]